鐳223用於轉移性賀爾蒙抗性攝護腺癌之治療劑量與臨床結果比較：

單一醫學中心治療經驗

蔡勝閔¹、劉建良²，蘇家震¹、李高漢¹、謝昆霖¹、黃冠華¹

台南永康奇美醫學中心 外科部 泌尿科¹，泌尿腫瘤科²

Comparison of Dosage and Clinical Outcome of Ra-223 in mCRPC: Real World Data from Single Center

Sheng-Min Tsai¹、Chien-Liang Liu¹、Chia-Cheng Su¹、Kau-Han Li¹、Kun-Lin Hsieh¹、Steven K. Huang¹

¹Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan;

²Division of Uro-Oncology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan;

Purpose:

Chemotherapy, novel hormonal agents and radium-223 have shown robust evidence of survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Besides, radium-223 has better health related quality of life (HRQoL) benefit in symptomatic patients. However, expensive medical cost of radium-223 is a major concern for patients. Radium-223 has been approved in Taiwan's National Health Insurance System since 2019 and the therapy of Radium-223 became affordable. Our aim is to review the patients underwent Radium-223 in our institution since 2019.

Material and Methods:

We retrospectively reviewed patients with prostate cancer and received treatment of Ra-223 at the Chi Mei Medical Center between 2019/1 and 2022/9. We excluded patients with mHSPC and visceral metastasis. In total, 28 patients were enrolled and categorized by dosage of Ra-223. The outcomes of interest included overall survival (OS), survival interval since Ra- 223 use and time to opioid use

Results:

The patients were divided into high dosage group (5 or 6 dosage) and incomplete treatment group (less then 4 dosage). The high dosage group has better OS (median 34.5 vs 12.5months) and superior survival interval since Ra-223 use (median 13 vs 4months). On comparison of time to opioid use, patients with 6 dosages have more benefit then 5 dosage and incomplete treatment group (median 13 vs 6 vs 3.5months).

Conclusion: